THUYA OCCIDENTALIS BOIRON MK GRAN. - interactions (all)

The risk or severity of adverse effects can be increased when Rufinamide is combined with Levodopa.
The risk or severity of adverse effects can be increased when Flumethasone is combined with Donepezil.
The serum concentration of Deutetrabenazine can be increased when it is combined with Ivacaftor.
The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Polythiazide.
The risk or severity of adverse effects can be increased when Tavaborole is combined with Amlodipine.
The metabolism of Befunolol can be decreased when combined with Amodiaquine.
The metabolism of Vilazodone can be decreased when combined with Pargyline.
The serum concentration of Chlorothiazide can be increased when it is combined with Trospium.
The risk or severity of adverse effects can be increased when Oxycodone is combined with Carbinoxamine.
Lisinopril may increase the arrhythmogenic activities of Ciprofloxacin.
The therapeutic efficacy of Phenformin can be decreased when used in combination with Paliperidone.
Clobetasone may increase the fluid retaining activities of Nandrolone decanoate.
Fibrinolysin may increase the anticoagulant activities of Acenocoumarol.
The therapeutic efficacy of Indapamide can be decreased when used in combination with Etanercept.
The risk or severity of adverse effects can be increased when Moexipril is combined with Iron.
Cimetidine may increase the myelosuppressive activities of Carmustine.
The risk or severity of adverse effects can be increased when Propantheline is combined with Desloratadine.
The risk or severity of adverse effects can be increased when Morphine is combined with Fosinopril.
The serum concentration of Erlotinib can be increased when it is combined with Ivacaftor.
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Tizanidine.
Salbutamol may increase the hypokalemic activities of Methyclothiazide.
The risk or severity of adverse effects can be increased when Methylene blue is combined with Salmeterol.
The serum concentration of Flurandrenolide can be increased when it is combined with Diethylstilbestrol.
Nicorandil may increase the hypotensive activities of Olmesartan.
The serum concentration of Brentuximab vedotin can be increased when it is combined with Dihydroergotamine.
The metabolism of Paclitaxel can be decreased when combined with Atazanavir.
The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Timolol.
The metabolism of Rosuvastatin can be decreased when combined with Erythromycin.
Roflumilast may increase the immunosuppressive activities of Methotrexate.
The serum concentration of Talinolol can be decreased when it is combined with Amobarbital.
Bisoprolol may decrease the bronchodilatory activities of Indacaterol.
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ethinyl Estradiol.
Thiamylal may increase the hypotensive activities of Diclofenamide.
The risk or severity of adverse effects can be increased when Methohexital is combined with Clemastine.
The metabolism of Loratadine can be decreased when combined with Cyclosporine.
The risk or severity of adverse effects can be increased when Lorazepam is combined with Secobarbital.
The serum concentration of Bendroflumethiazide can be increased when it is combined with Tubocurarine.
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Nabilone may increase the tachycardic activities of Isoprenaline.
Furazolidone may increase the hypotensive activities of Fosinopril.
The risk or severity of adverse effects can be increased when Pipamperone is combined with Lisinopril.
Prazosin may increase the hypotensive activities of Guanethidine.
Salsalate may decrease the excretion rate of Neomycin which could result in a higher serum level.
The serum concentration of Tolmetin can be increased when it is combined with Probenecid.
The therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Acitretin.
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benazepril.
The metabolism of Brinzolamide can be decreased when combined with Verapamil.
The metabolism of Testosterone can be increased when combined with Nevirapine.
Fluvoxamine may increase the hypoglycemic activities of Metformin.
The serum concentration of Topotecan can be increased when it is combined with Dasabuvir.
Linagliptin may increase the hypoglycemic activities of Sulfisoxazole.
The metabolism of Eltrombopag can be decreased when combined with Trimethoprim.
The serum concentration of Metoprolol can be increased when it is combined with Cyproterone acetate.
The risk or severity of adverse effects can be increased when Piritramide is combined with Clopamide.
The risk or severity of adverse effects can be increased when Enalapril is combined with Iron Dextran.
The serum concentration of Vemurafenib can be increased when it is combined with Atazanavir.
The metabolism of Alclometasone can be decreased when combined with Clotrimazole.
Benmoxin may increase the hypertensive activities of Ergotamine.
The serum concentration of Bisoprolol can be increased when it is combined with Propafenone.
The serum concentration of Vincristine can be increased when it is combined with Meprobamate.
The risk or severity of adverse effects can be increased when Griseofulvin is combined with Clevidipine.
The metabolism of Ombitasvir can be decreased when combined with Rabeprazole.
The metabolism of Betaxolol can be decreased when combined with Isoniazid.
Balsalazide may increase the nephrotoxic activities of Cyclosporine.
The serum concentration of Mirabegron can be increased when it is combined with Cobicistat.
The risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketoprofen.
The metabolism of Argatroban can be decreased when combined with Darunavir.
Platelet Activating Factor may increase the hypotensive activities of Candesartan.
The serum concentration of Midazolam can be increased when it is combined with Alogliptin.
The therapeutic efficacy of Indapamide can be decreased when used in combination with Tranilast.
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mizoribine.
The risk or severity of adverse effects can be increased when Dyclonine is combined with Gepirone.
The risk or severity of adverse effects can be increased when Aclidinium is combined with Levomethadyl Acetate.
The risk or severity of adverse effects can be increased when Enalapril is combined with Meloxicam.
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Deramciclane.
The serum concentration of Sildenafil can be increased when it is combined with Sitagliptin.
The risk or severity of adverse effects can be increased when Aclidinium is combined with Ethylmorphine.
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Everolimus.
Alfuzosin may decrease the vasoconstricting activities of Synephrine.
The serum concentration of Venlafaxine can be increased when it is combined with Cobicistat.
Valsartan may increase the hypotensive activities of Alprenolol.
The risk or severity of adverse effects can be increased when Diflunisal is combined with Desonide.
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Dexamethasone.
The serum concentration of Tolvaptan can be increased when it is combined with Pilocarpine.
The risk or severity of adverse effects can be increased when Mepivacaine is combined with Carisoprodol.
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Melperone.
The risk or severity of adverse effects can be increased when Quinapril is combined with Tiaprofenic acid.
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxprenolol.
The serum concentration of Dienogest can be decreased when it is combined with Eslicarbazepine acetate.
The therapeutic efficacy of Mefloquine can be decreased when used in combination with Sarilumab.
Travoprost may increase the hypotensive activities of Chlorothiazide.
Caroxazone may increase the hypertensive activities of Phenylephrine.
Heparin may increase the hyperkalemic activities of Cilazapril.
Framycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
The risk or severity of adverse effects can be increased when Methoxamine is combined with Fenoterol.
The metabolism of Tolbutamide can be decreased when combined with Isoniazid.
The risk or severity of adverse effects can be increased when Rotigotine is combined with Valsartan.
Pargyline may increase the hypoglycemic activities of Repaglinide.
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin Enacarbil.
The serum concentration of Buprenorphine can be increased when it is combined with Ombitasvir.
The serum concentration of Etodolac can be increased when it is combined with Probenecid.
The risk or severity of adverse effects can be increased when Olmesartan is combined with Tolfenamic Acid.
Guanethidine may increase the hypotensive activities of Talinolol.
Oxitropium may increase the anticholinergic activities of Umeclidinium.
The metabolism of Chlorphenamine can be decreased when combined with Nilotinib.
Bendroflumethiazide may increase the bradycardic activities of Pasireotide.
The bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate.
The metabolism of Brompheniramine can be decreased when combined with Cocaine.
The risk or severity of adverse effects can be increased when Zileuton is combined with Fluticasone furoate.
Secobarbital may increase the hypotensive activities of Benazepril.
The risk or severity of adverse effects can be increased when Benzydamine is combined with Flurandrenolide.
The risk or severity of adverse effects can be increased when Cocaine is combined with clomethiazole.
The therapeutic efficacy of Heparin can be decreased when used in combination with Medrogestone.
The risk or severity of adverse effects can be increased when Apocynin is combined with Flunisolide.
The metabolism of Dutasteride can be decreased when combined with Isavuconazonium.
The metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.
The serum concentration of Atazanavir can be decreased when it is combined with Deferasirox.
Xylometazoline may increase the atrioventricular blocking (AV block) activities of Nebivolol.
Bufexamac may decrease the diuretic activities of Torasemide.
Droxidopa may increase the hypokalemic activities of Hydrochlorothiazide.
Magnesium salicylate may increase the hyperkalemic activities of Drospirenone.
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.
The metabolism of Toremifene can be decreased when combined with Sulfisoxazole.
Ibuprofen may decrease the antihypertensive activities of Landiolol.
The risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline.
Estrone may decrease the anticoagulant activities of Pentosan Polysulfate.
The metabolism of Frovatriptan can be decreased when combined with Clotrimazole.
The metabolism of Dapsone can be increased when combined with Fosphenytoin.
Udenafil may increase the antihypertensive activities of Cyclothiazide.
The risk or severity of adverse effects can be increased when DPDPE is combined with Cyclopenthiazide.